BELLUS Health BLU shares are trading higher. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock.
BELLUS Health's stock is trading up 23.33% to a price of $5.9. The stock's current volume for the day is 34.87 million, which is approximately 1958.62% of its previous 30-day average volume of 1.78 million.
The 50-day moving average price of BELLUS Health's stock was $3.21 when this article was published. The stock reached a high of $5.15 and a low of $2.01 in the past 52 weeks.
If you're looking for timely and concise explanations of why a stock is moving, check out Benzinga Pro. Subscribers get ‘Why Is It Moving' alerts as soon as our research team identifies the cause of the price action in a stock. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.